➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Baxter
Mallinckrodt
Medtronic

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

DEFEROXAMINE MESYLATE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Deferoxamine Mesylate patents expire, and when can generic versions of Deferoxamine Mesylate launch?

Deferoxamine Mesylate is a drug marketed by Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, and West-ward Pharms Int. and is included in five NDAs.

The generic ingredient in DEFEROXAMINE MESYLATE is deferoxamine mesylate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Deferoxamine Mesylate

A generic version of DEFEROXAMINE MESYLATE was approved as deferoxamine mesylate by HOSPIRA on March 17th, 2004.

  Free Forever Trial

Drug patent expirations by year for DEFEROXAMINE MESYLATE
Drug Prices for DEFEROXAMINE MESYLATE

See drug prices for DEFEROXAMINE MESYLATE

Recent Clinical Trials for DEFEROXAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Michigan Medicine PKUHSC Joint Institute for Translational & Clinical ResearchPhase 2
Aditya S. Pandey, MDPhase 2
Beijing Jishuitan HospitalPhase 1/Phase 2

See all DEFEROXAMINE MESYLATE clinical trials

Pharmacology for DEFEROXAMINE MESYLATE
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Medical Subject Heading (MeSH) Categories for DEFEROXAMINE MESYLATE
Anatomical Therapeutic Chemical (ATC) Classes for DEFEROXAMINE MESYLATE

US Patents and Regulatory Information for DEFEROXAMINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076806-002 Mar 31, 2006 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Hospira DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076019-002 Mar 17, 2004 AP RX No Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Fresenius Kabi Usa DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 078718-001 Sep 15, 2009 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Hospira DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076019-001 Mar 17, 2004 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Dr Reddys DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 076806-001 Mar 31, 2006 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Fresenius Kabi Usa DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 078718-002 Sep 15, 2009 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Gland Pharma Ltd DEFEROXAMINE MESYLATE deferoxamine mesylate INJECTABLE;INJECTION 207384-001 Sep 29, 2017 AP RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Baxter
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.